Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A.

Acta Neuropathol. 2009 Oct;118(4):469-74. doi: 10.1007/s00401-009-0561-9. Epub 2009 Jun 25.

PMID:
19554337
2.

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C.

Acta Neuropathol. 2009 Sep;118(3):401-5. doi: 10.1007/s00401-009-0550-z. Epub 2009 Jun 19.

PMID:
19543740
3.

Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.

Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, Jones TA, Aarum J, Dalton J, Bailey S, Chaplin T, Carter RL, Gajjar A, Broniscer A, Young BD, Ellison DW, Sheer D.

J Pathol. 2009 Jun;218(2):172-81. doi: 10.1002/path.2558.

PMID:
19373855
4.

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, Bosenberg M.

Nat Genet. 2009 May;41(5):544-52. doi: 10.1038/ng.356. Epub 2009 Mar 12.

5.

IDH1 and IDH2 mutations in gliomas.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD.

N Engl J Med. 2009 Feb 19;360(8):765-73. doi: 10.1056/NEJMoa0808710.

6.

MAP'ing CNS development and cognition: an ERKsome process.

Samuels IS, Saitta SC, Landreth GE.

Neuron. 2009 Jan 29;61(2):160-7. doi: 10.1016/j.neuron.2009.01.001. Review.

7.

Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene.

Sievert AJ, Jackson EM, Gai X, Hakonarson H, Judkins AR, Resnick AC, Sutton LN, Storm PB, Shaikh TH, Biegel JA.

Brain Pathol. 2009 Jul;19(3):449-58. doi: 10.1111/j.1750-3639.2008.00225.x. Epub 2008 Oct 21. Erratum in: Brain Pathol. 2009 Jul;19(3):550.

8.

Analysis of the IDH1 codon 132 mutation in brain tumors.

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A.

Acta Neuropathol. 2008 Dec;116(6):597-602. doi: 10.1007/s00401-008-0455-2. Epub 2008 Nov 5.

PMID:
18985363
9.

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, Collins VP.

Cancer Res. 2008 Nov 1;68(21):8673-7. doi: 10.1158/0008-5472.CAN-08-2097.

10.

KRAS mutation profile in colorectal carcinoma and novel mutation--internal tandem duplication in KRAS.

Wójcik P, Kulig J, Okoń K, Zazula M, Moździoch I, Niepsuj A, Stachura J.

Pol J Pathol. 2008;59(2):93-6.

PMID:
18669174
11.

Comprehensive characterization of genomic aberrations in gangliogliomas by CGH, array-based CGH and interphase FISH.

Hoischen A, Ehrler M, Fassunke J, Simon M, Baudis M, Landwehr C, Radlwimmer B, Lichter P, Schramm J, Becker AJ, Weber RG.

Brain Pathol. 2008 Jul;18(3):326-37. doi: 10.1111/j.1750-3639.2008.00122.x. Epub 2008 Mar 26.

PMID:
18371186
12.

BRAF(E600) in benign and malignant human tumours.

Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS.

Oncogene. 2008 Feb 7;27(7):877-95. Epub 2007 Aug 27. Review.

PMID:
17724477
13.

Atypical teratoid/rhabdoid tumor arising in the setting of a pleomorphic xanthoastrocytoma.

Chacko G, Chacko AG, Dunham CP, Judkins AR, Biegel JA, Perry A.

J Neurooncol. 2007 Sep;84(2):217-22. Epub 2007 Apr 13.

PMID:
17431546
14.

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T.

Br J Cancer. 2007 Apr 23;96(8):1166-9. Epub 2007 Mar 20.

15.

Malignant and benign ganglioglioma: a pathological and molecular study.

Pandita A, Balasubramaniam A, Perrin R, Shannon P, Guha A.

Neuro Oncol. 2007 Apr;9(2):124-34. Epub 2007 Jan 26.

16.

Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.

Weber RG, Hoischen A, Ehrler M, Zipper P, Kaulich K, Blaschke B, Becker AJ, Weber-Mangal S, Jauch A, Radlwimmer B, Schramm J, Wiestler OD, Lichter P, Reifenberger G.

Oncogene. 2007 Feb 15;26(7):1088-97. Epub 2006 Aug 7.

PMID:
16909113
17.

High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping.

Peiffer DA, Le JM, Steemers FJ, Chang W, Jenniges T, Garcia F, Haden K, Li J, Shaw CA, Belmont J, Cheung SW, Shen RM, Barker DL, Gunderson KL.

Genome Res. 2006 Sep;16(9):1136-48. Epub 2006 Aug 9.

18.

Long-term seizure outcome following surgery for dysembryoplastic neuroepithelial tumor.

Chan CH, Bittar RG, Davis GA, Kalnins RM, Fabinyi GC.

J Neurosurg. 2006 Jan;104(1):62-9.

PMID:
16509148
19.

Atypical teratoid/rhabdoid tumor evolving from an optic pathway ganglioglioma: case study.

Allen JC, Judkins AR, Rosenblum MK, Biegel JA.

Neuro Oncol. 2006 Jan;8(1):79-82.

20.

Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.

Uribe P, Andrade L, Gonzalez S.

J Invest Dermatol. 2006 Jan;126(1):161-6.

Supplemental Content

Support Center